Cue Biopharma (CUE) Receivables - Net (2019 - 2026)

Cue Biopharma has disclosed Receivables - Net across 8 years of filings, most recently posting $5.4 million for Q2 2026.

• In Q2 2026, Receivables - Net rose 910.71% year-over-year to $5.4 million; the TTM figure through Jun 2026 stood at $5.4 million (up 910.71% YoY), while the FY2025 annual figure was $5.5 million, up 486.88% from the prior year.
• Receivables - Net came in at $5.4 million for Q2 2026 at Cue Biopharma, down from $5.5 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $5.5 million in Q4 2025 to a low of $57000.0 in Q4 2022.
• Average Receivables - Net over 5 years is $1.6 million, with a median of $1.0 million recorded in 2023.
• Year-over-year, Receivables - Net slumped 98.19% in 2022 and jumped 2878.95% in 2023.
• Over 5 years, Receivables - Net stood at $57000.0 in 2022, then jumped by 2878.95% to $1.7 million in 2023, then slumped by 44.35% to $945000.0 in 2024, then surged by 486.88% to $5.5 million in 2025, then declined by 3.05% to $5.4 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $5.4 million in Q2 2026, $5.5 million in Q4 2025, and $387000.0 in Q3 2025.